Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 3
2003 2
2004 1
2006 1
2007 8
2008 3
2009 5
2010 12
2011 19
2012 12
2013 26
2014 23
2015 34
2016 36
2017 27
2018 41
2019 44
2020 44
2021 27
2022 38
2023 45
2024 49
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Results by year

Filters applied: . Clear all
Page 1
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.
Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. Zhang SM, et al. Nature. 2021 Oct;598(7882):682-687. doi: 10.1038/s41586-021-03994-2. Epub 2021 Oct 20. Nature. 2021. PMID: 34671158 Free PMC article.
Mechanistically, KDM5B recruits the H3K9 methyltransferase SETDB1 to repress endogenous retroelements such as MMVL30 in a demethylase-independent manner. Derepression of these retroelements activates cytosolic RNA-sensing and DNA-sensing pathways and the subsequent type-I …
Mechanistically, KDM5B recruits the H3K9 methyltransferase SETDB1 to repress endogenous retroelements such as MMVL30 in a demethylase …
Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16/TOP2A axis.
Zhang B, Li J, Wang Y, Liu X, Yang X, Liao Z, Deng S, Deng Y, Zhou Z, Tian Y, Wei W, Meng J, Hu Y, Wan C, Zhang Z, Huang F, Wen L, Wu B, Sun Y, Li Y, Yang K. Zhang B, et al. Cell Death Differ. 2024 Mar;31(3):309-321. doi: 10.1038/s41418-024-01257-x. Epub 2024 Jan 29. Cell Death Differ. 2024. PMID: 38287116 Free PMC article.
In addition, we showed that the deubiquitinase USP7 was critical for deubiquitinating and stabilizing KDM5B. More importantly, the deletion of USP7 increased sensitivity to cisplatin by disrupting the stability of KDM5B in NPC cells. Therefore, our findings demonstr …
In addition, we showed that the deubiquitinase USP7 was critical for deubiquitinating and stabilizing KDM5B. More importantly, the de …
KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
Xhabija B, Kidder BL. Xhabija B, et al. Semin Cancer Biol. 2019 Aug;57:79-85. doi: 10.1016/j.semcancer.2018.11.001. Epub 2018 Nov 16. Semin Cancer Biol. 2019. PMID: 30448242 Free PMC article. Review.
KDM5B is also overexpressed, amplified, or mutated in many cancer types. In cancer cells, KDM5B regulates expression of oncogenes and tumor suppressors by modulating H3K4 methylation levels. In this review, we examine how KDM5B regulates gene expression and c …
KDM5B is also overexpressed, amplified, or mutated in many cancer types. In cancer cells, KDM5B regulates expression of oncoge …
Targeting histone demethylase KDM5B for cancer treatment.
Fu YD, Huang MJ, Guo JW, You YZ, Liu HM, Huang LH, Yu B. Fu YD, et al. Eur J Med Chem. 2020 Dec 15;208:112760. doi: 10.1016/j.ejmech.2020.112760. Epub 2020 Aug 21. Eur J Med Chem. 2020. PMID: 32883639 Review.
KDM5B functions as an oncogene and associates with human cancers closely. Targeting KDM5B has been a promising direction for curing cancer since the emergence of potent KDM5B inhibitor CPI-455. ...We hope to provide a comprehensive overview of KDM5B an …
KDM5B functions as an oncogene and associates with human cancers closely. Targeting KDM5B has been a promising direction for c …
Histone Demethylase KDM5B as a Therapeutic Target for Cancer Therapy.
Jose A, Shenoy GG, Sunil Rodrigues G, Kumar NAN, Munisamy M, Thomas L, Kolesar J, Rai G, Rao PPN, Rao M. Jose A, et al. Cancers (Basel). 2020 Jul 31;12(8):2121. doi: 10.3390/cancers12082121. Cancers (Basel). 2020. PMID: 32751840 Free PMC article. Review.
Identification of molecules targeting the KDM5B enzyme could be a potential lead in cancer research. Although many KDM5B inhibitors with promising outcomes have been developed so far, its further application in clinical practice is limited due to toxicity and lack o …
Identification of molecules targeting the KDM5B enzyme could be a potential lead in cancer research. Although many KDM5B inhib …
Pathogenic KDM5B variants in the context of developmental disorders.
Harrington J, Wheway G, Willaime-Morawek S, Gibson J, Walters ZS. Harrington J, et al. Biochim Biophys Acta Gene Regul Mech. 2022 Jul;1865(5):194848. doi: 10.1016/j.bbagrm.2022.194848. Epub 2022 Jul 26. Biochim Biophys Acta Gene Regul Mech. 2022. PMID: 35905858 Free article. Review.
KDM5B is responsible for the demethylation of lysine 4 on the amino tail of histone 3 and plays a vital role in normal development and regulating cell differentiation. This review explores the literature on KDM5B and what is currently known about its roles in develo …
KDM5B is responsible for the demethylation of lysine 4 on the amino tail of histone 3 and plays a vital role in normal development an …
Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Zheng YC, Chang J, Wang LC, Ren HM, Pang JR, Liu HM. Zheng YC, et al. Eur J Med Chem. 2019 Jan 1;161:131-140. doi: 10.1016/j.ejmech.2018.10.040. Epub 2018 Oct 17. Eur J Med Chem. 2019. PMID: 30343192 Review.
Lysine demethylase 5B (KDM5B) is a histone demethylase identified in 2007, which is responsible for erasing H3K4me2/3 activation marker. ...This review focuses on the basic biochemical and physiological function of KDM5B and its involved mechanisms in cancers, a com …
Lysine demethylase 5B (KDM5B) is a histone demethylase identified in 2007, which is responsible for erasing H3K4me2/3 activation mark …
Histone demethylase KDM5B licenses macrophage-mediated inflammatory responses by repressing Nfkbia transcription.
Zhang Y, Gao Y, Jiang Y, Ding Y, Chen H, Xiang Y, Zhan Z, Liu X. Zhang Y, et al. Cell Death Differ. 2023 May;30(5):1279-1292. doi: 10.1038/s41418-023-01136-x. Epub 2023 Mar 13. Cell Death Differ. 2023. PMID: 36914768 Free PMC article.
KDM5B deficiency or inhibitor treatment protected mice from immunologic injury in both collagen-induced arthritis (CIA) model and endotoxin shock model. Genome-wide analysis of KDM5B-binding peaks identified that KDM5B was selectively recruited to the promote …
KDM5B deficiency or inhibitor treatment protected mice from immunologic injury in both collagen-induced arthritis (CIA) model and end …
KDM5B predicts temozolomide-resistant subclones in glioblastoma.
Ullrich V, Ertmer S, Baginska A, Dorsch M, Gull HH, Cima I, Berger P, Dobersalske C, Langer S, Meyer L, Dujardin P, Kebir S, Glas M, Blau T, Keyvani K, Rauschenbach L, Sure U, Roesch A, Grüner BM, Scheffler B. Ullrich V, et al. iScience. 2023 Dec 3;27(1):108596. doi: 10.1016/j.isci.2023.108596. eCollection 2024 Jan 19. iScience. 2023. PMID: 38174322 Free PMC article.
Knockdown of KDM5B reverses pAKT levels, simultaneously increasing PTEN expression and TMZ sensitivity. ...Thus, KDM5B(high) treatment-naive cells preferentially contribute to the dynamics of drug resistance under TMZ. ...
Knockdown of KDM5B reverses pAKT levels, simultaneously increasing PTEN expression and TMZ sensitivity. ...Thus, KDM5B(high) t …
Loss of KDM5B ameliorates pathological cardiac fibrosis and dysfunction by epigenetically enhancing ATF3 expression.
Wang B, Tan Y, Zhang Y, Zhang S, Duan X, Jiang Y, Li T, Zhou Q, Liu X, Zhan Z. Wang B, et al. Exp Mol Med. 2022 Dec;54(12):2175-2187. doi: 10.1038/s12276-022-00904-y. Epub 2022 Dec 8. Exp Mol Med. 2022. PMID: 36481938 Free PMC article.
Here, we identified lysine demethylase 5B (KDM5B), a histone H3K4me2/me3 demethylase, as a key epigenetic mediator of pathological cardiac fibrosis. KDM5B expression was upregulated in cardiac fibroblasts and myocardial tissues in response to pathological stress. .. …
Here, we identified lysine demethylase 5B (KDM5B), a histone H3K4me2/me3 demethylase, as a key epigenetic mediator of pathological ca …
463 results